RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)

August 31, 2026 8:40 AM

RBC Capital analyst Luca Issi reiterated an Outperform rating and $100.00 price target on Arrowhead Pharma ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found